[The role of mucolytic therapy in the treatment of sinobronchial syndrome].
The objective of the present study was to estimate the therapeutic efficacy and safety of myrtol standardized (gelomyrtol forte) and acetylcysteine given to 11 and 13 patients respectively presenting with sinobronchial syndrome. Dynamics of clinical and roentgenological signs and symptoms in these patients was investigated throughout the period of therapy. The best clinical results were obtained using myrtol standardized. Specifically, the summary score characterizing the change of clinical symptoms decreased from the initial value of 32 to 0.73 on the 7th day after the initiation of therapy and to 0.18 after its termination. The decrease of the same parameter in the group of the patients treated with acetylcysteine to 1.3 and 0.38 (mean score for the group) was documented on days 7 and 10 after the beginning of therapy respectively.
O V
OV
Zaĭtseva
D000111:Acetylcysteine / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations; D005100:Expectorants / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D039821:Monoterpenes / Q000627:therapeutic use*; D012852:Sinusitis / Q000188:drug therapy*; D013577:Syndrome
D004338:Drug Combinations; D005100:Expectorants; D039821:Monoterpenes; C055632:myrtol; D000111:Acetylcysteine